The E&M Affiliate Luka AI Cell Completes 'Prevention-Diagnosis-Treatment' Product Lineup to Prepare for the Next Pandemic

The D&M announced that its affiliate, Luca AI Cell (hereinafter ‘Luca’), has completed the full lineup of bio products to prepare in advance for the next pandemic.

A company representative said, “Recently, the number of COVID-19 confirmed cases has exceeded tens of thousands per day, raising concerns about a resurgence,” adding, “However, with the government easing quarantine measures, careful attention and responsibility for infection prevention are expected to fall on individuals.” He further expressed hope, stating, “It is anticipated that Luca’s product lineup will help prepare for reinfection.”

Previously, Luca released the ‘LUCA COVID-19 Ag Nasal Home Test,’ which applies its core technology LLBTM (LUCA Lipid Bilayer) to improve accuracy and reduce testing time to within 5 minutes. This kit is known as a groundbreaking product capable of detecting all COVID-19 variants, including the recently dominant XBB strain.

The subsequently launched ‘LUCA V-Defense Nasal Spray’ forms a protective barrier on the nasal mucosa, the infection route of COVID-19. It has proven its safety by obtaining certifications from the Korea Food and Drug Administration, the U.S. FDA, and the European CE. Additionally, it is free from steroids, antihistamines, and methazoline-class ingredients, thus avoiding issues related to resistance or side effects. This product contains active ingredients extracted from natural red algae called ‘Lambda Carrageenan’ and antimicrobial lipids, making it safe for use by children and pregnant women.

Dr. Namjun Cho, Luca’s Chief Technology Officer, leads the ‘Antiviral Therapeutics Using Peptides,’ which was selected for the AViDD (Antiviral Drug Discovery) program by the U.S. NIAID (National Institute of Allergy and Infectious Diseases). AViDD is a program designed to prepare for future infectious disease pandemics. According to the company, efficacy and effectiveness tests targeting various viruses such as COVID-19, dengue fever, and Rabies Virus are being conducted domestically as well as in the U.S., Thailand, Japan, Brazil, and other countries.

A company representative stated, “Not only the product lineup for next pandemic preparedness but also research and development results in various fields utilizing universal antiviral peptides and artificial cell membrane core technologies are becoming visible,” and added, “We will continue to showcase ongoing achievements in the future.”

This content was produced with the assistance of AI translation services.